Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 30(3): 271-4, 2010 Mar.
Artículo en Chino | MEDLINE | ID: mdl-20535925

RESUMEN

OBJECTIVE: To study the effect of strengthening Pi and nourishing Shen therapy (SPNST) in treating patients with glucocorticoid resistant myasthenia gravis (GR-MG). METHODS: Twenty-seven patients with MG were enrolled, who were relapse cases after treated by cholinesterase inhibitor with systemic glucocorticoid treatment and showed resistance to glucocorticoid. All were treated by Western medicines, methylprednisolone (MP) and pyridostigmine bromide (PSB), together with Chinese medicine (CM) given according to their syndrome types, namely, for the 15 patients of Pi-Shen qi-yin deficiency type, Buzhong Yiqi Pill and Liuwei Dihuang Pill, and for the 12 patients of Pi-Shen yang-deficiency type, Buzhong Yiqi Pill and Zishen Yutai Pill. The dosages of medicines were reduced gradually in MP-PSB-CM order along with the progressing of the therapy in 4 stages (symptom curing, choline receptor restoration, immune regulation, and functional strengthening). Muscle strength and overall state of patients were re-examined before and after each of the 4 stages. RESULTS: After 1-year treatment, the therapeutic effect in 9 patients was judged as completely remitted; in 7 as remitted with continuous medication; in 5, 1 and 3 as significantly improved, moderately improved and unchanged respectively, while 2 patients died. CONCLUSION: Integrative medicine shows definite effects in treating GR-MG, and it is worthy of further studying.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Medicina Integrativa/métodos , Miastenia Gravis/tratamiento farmacológico , Deficiencia Yin/tratamiento farmacológico , Adolescente , Adulto , Anciano , Resistencia a Medicamentos , Femenino , Glucocorticoides/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven
3.
Zhong Yao Cai ; 29(10): 1056-8, 2006 Oct.
Artículo en Chino | MEDLINE | ID: mdl-17326407

RESUMEN

OBJECTIVE: To investigate the effect on bone marrow stem cell transplantition (BMST) combinated with Bushen fang therapy in mdx mice. METHODS: Cultured the bone marrow cells of C56BL/6 in vitro and tranplante these cells to mdx mice after irradiation. Bushen fang was used to cure the mdx mice after BMST. The survivel rate, symptom of Graft Versus Host Disease (GVHD) and motor function of model mice following irradiation and transplantation were observed 4 or 8 months after BMST, prepared the freeze-splice of muscles of each group, and made HE staining. The dystrophin (DYS) was detected by SABC immunofluorescene. RESULTS: Bushen fang could decrease the rate of centrally nucleated fibers (CNF), enhance expressional rate of DYS in different level and relieve the symptom of GVHD in transplanted mice. CONCLUSION: Bushen fang can improve the therapeutic efficacy of BMST.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Trasplante de Células Madre Hematopoyéticas , Distrofia Muscular de Duchenne/terapia , Animales , Terapia Combinada , Distrofina/biosíntesis , Femenino , Enfermedad Injerto contra Huésped/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos mdx , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Distrofia Muscular de Duchenne/tratamiento farmacológico , Distrofia Muscular de Duchenne/mortalidad , Fitoterapia , Plantas Medicinales/química , Tasa de Supervivencia
4.
Zhonghua Er Ke Za Zhi ; 41(9): 657-60, 2003 Sep.
Artículo en Chino | MEDLINE | ID: mdl-14733803

RESUMEN

OBJECTIVE: Asthma is a chronic respiratory tract disorder characterized by airway hyperreaction (AHR), persistent airway inflammation, high serum IgE, overproduction of IL-4, IL-5 and IL-13 by allergen-specific Th2 cells. The morbidity and mortality of asthma have continued to increase despite the use of currently available therapeutic agents. The reputed effects of traditional Chinese medicines (TCMs) have led to increasing use of TCMs for treatment of asthma throughout the world. The aims of this study were to investigate in asthma model of young rat the mRNA expressions of apoptotic gene fas and bcl-2, eosinophils (EOS) apoptosis in airway, and effects of achyranthes bidentata polysaccharides (ABPS), a group of polysaccharides extracted from TCM Achyranthes bidentata blume, on treatment of asthma. METHODS: Fifty Sprague-Dawley (SD) rats were divided into five groups, 10 rats per group. Asthma in rats was induced by intraperitioneal sensitization and challenge with nebulized ovalbumin (OVA). A pretreatment with ABPS [50 mg/(kg x d)] was done according to three different schedules: consecutively 3 days at sensitization (T1), at challenge (T2) or both of the two periods (T3). Sham-treated rats (A) and naive rats (C) served as controls. The animals were sacrificed 24 hours after the last challenge. The mRNA expression of bcl-2 and fas in eosinophils presenting in airway and the apoptosis of eosinophils in airway were assessed by using in situ hybridization with oligonucleotide probe and TUNEL methods, respectively. RESULTS: (1) Twenty-four hours after the last antigen challenge, the mRNA expression of fas in eosinophils presenting in airway significantly decreased in group A [(43.4 +/- 10.0)%] compared with that in group C [(73.2 +/- 11.9)%] (P < 0.01). ABPS could increase the fas mRNA expression significantly in all the three groups [(59.0 +/- 8.1)%, (57.5 +/- 9.6)%, (76.2 +/- 2.7)%], compared with that in group A (P < 0.05, P < 0.05, P < 0.01, respectively). The expression of the bcl-2 mRNA in group C was (47.9 +/- 8.7)%, it was elevated to (67.4 +/- 7.3)% in group A (P < 0.01). The expression of the bcl-2 mRNA in ABPS treated T1 and T3 groups was significantly lowered [(57.7 +/- 12.7)%, (57.3 +/- 6.8)%, P < 0.05], but not in T2 group [(72.4 +/- 6.7)%]. (2) In group A, the EOS presenting in the airway increased significantly, but there were few apoptotic EOS; the percentage of apoptotic eosinophil was distinctly lower in group A than that in group C [(5.3 +/- 2.2)% vs. (15.9 +/- 2.4)%, P < 0.01]. Compared with that in group A, the eosinophil apoptosis ratio in those ABPS treated groups T1, T3 was evidently elevated [(8.7 +/- 2.9)%, (9.8 +/- 2.2)%, P < 0.05, P < 0.05], but ABPS treated at challenge (T2) could not change the eosinophil apoptosis ratio significantly (P > 0.05). CONCLUSION: (1) In asthmatic rat, the expressions of the genes fas and bcl-2 mRNA in EOS were changed evidently and the ratio of EOS apoptotosis reduced greatly. (2) ABPS could enhance the apoptosis of EOS by upregulating the expression of the genes fas and bcl-2 mRNA.


Asunto(s)
Apoptosis/efectos de los fármacos , Asma/tratamiento farmacológico , Eosinófilos/metabolismo , Genes bcl-2/genética , Neuropéptidos/genética , Polisacáridos/uso terapéutico , Receptores del Factor de Necrosis Tumoral , Achyranthes/química , Animales , Apoptosis/genética , Asma/etiología , Modelos Animales de Enfermedad , Eosinófilos/efectos de los fármacos , Hibridación in Situ , Etiquetado Corte-Fin in Situ , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Pulmón/patología , Masculino , Ovalbúmina/administración & dosificación , Fitoterapia , Extractos Vegetales/química , Extractos Vegetales/uso terapéutico , ARN Mensajero/efectos de los fármacos , ARN Mensajero/genética , ARN Mensajero/metabolismo , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Receptor fas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA